Urban Marian, Booth Karen, Jungschleger Jerome, Netuka Ivan, Schueler Stephan, MacGowan Guy
Division of Cardiothoracic Surgery, Department of Surgery, University of Nebraska Medical Center, Omaha, NE, USA.
Department of Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, UK.
Interact Cardiovasc Thorac Surg. 2019 Mar 1;28(3):455-464. doi: 10.1093/icvts/ivy262.
This study aimed to quantify the impact of donor variables on post-heart transplantation mortality and morbidity in recipients with and without a pretransplant left ventricular assist device (LVAD).
This is a prospective cohort study of the ISHLT Transplant Registry that includes all primary heart transplants in adult recipients (January 2005-June 2013, n = 15 532). All recipients were divided into patients with a durable continuous-flow LVAD (LVAD recipient, n = 3315) and without mechanical support (standard recipient, n = 12 217). Donors were classified as high risk (n = 3751) and low risk (n = 11 781). Transplants were categorized into low-risk donor/standard recipient (n = 9214), high-risk donor/standard recipient (n = 3003), low-risk donor/LVAD recipient (n = 2567) and high-risk donor/LVAD recipient (n = 748). Outcomes prior to discharge, survival at 5 years and freedom from complications were computed for each group.
LVAD recipients experienced more episodes of infection, stroke and acute rejection with both low- (P < 0.001, P < 0.001, P < 0.001) and high-risk donors (P < 0.001, P = 0.008, P = 0.028) prior to transplant discharge. Within standard recipients, a higher rate of primary graft failure (P = 0.035), infection (P = 0.001), dialysis (P = 0.012), acute rejection (P = 0.037) and less freedom from cardiac allograft vasculopathy (P < 0.001) and malignancy (P = 0.004) was observed with high-risk donors. Within LVAD recipients, no differences in complications prior to discharge or long-term morbidity were detected between low- and high-risk donors. When compared to standard recipient/low-risk donors, all the 3 remaining categories had an increased probability of death or graft failure within 90 days: LVAD recipient/low-risk donor [hazard ratio (HR) 1.26, confidence interval (CI) 1.05-1.51; P = 0.012], standard recipient/high-risk donor (HR 1.47, CI 1.27-1.71; P < 0.001) and LVAD recipient/high-risk donor (HR 1.72, CI 1.32-2.24; P < 0.001). Between 90 days and 5 years, only standard recipient/high-risk donor had an increased probability of death or graft failure (HR 1.140, CI 1.020-1.274; P = 0.021) when compared to standard recipient/low-risk donor.
LVAD recipients, whether with high- or low-risk donors, have worse early (but not late) survival and more early complications than those of standard recipients. We found that adverse donor characteristics are less predictive for determining the outcome of LVAD-bridged recipients than standard recipients.
本研究旨在量化供体变量对接受和未接受移植前左心室辅助装置(LVAD)的受体心脏移植后死亡率和发病率的影响。
这是一项对国际心脏和肺移植学会(ISHLT)移植登记处的前瞻性队列研究,纳入了成年受体的所有初次心脏移植病例(2005年1月至2013年6月,n = 15532)。所有受体被分为接受持久连续流LVAD的患者(LVAD受体,n = 3315)和未接受机械支持的患者(标准受体,n = 12217)。供体被分为高风险(n = 3751)和低风险(n = 11781)。移植被分为低风险供体/标准受体(n = 9214)、高风险供体/标准受体(n = 3003)、低风险供体/LVAD受体(n = 2567)和高风险供体/LVAD受体(n = 748)。计算每组出院前的结局、5年生存率和无并发症情况。
LVAD受体在移植出院前,接受低风险(P < 0.001,P < 0.001,P < 0.001)和高风险供体(P < 0.001,P = 0.008,P = 0.028)时,感染、中风和急性排斥发作更多。在标准受体中,高风险供体的原发性移植物功能衰竭发生率更高(P = 0.035)、感染(P = 0.001)、透析(P = 0.012)、急性排斥(P = 0.037),且心脏同种异体血管病变(P < 0.001)和恶性肿瘤(P = 0.004)的无病生存期更短。在LVAD受体中,低风险和高风险供体在出院前并发症或长期发病率方面未检测到差异。与标准受体/低风险供体相比,其余3组在90天内死亡或移植物失败的概率均增加:LVAD受体/低风险供体[风险比(HR)1.26,置信区间(CI)1.05 - 1.51;P = 0.012]、标准受体/高风险供体(HR 1.47,CI 1.27 - 1.71;P < 0.001)和LVAD受体/高风险供体(HR 1.72,CI 1.32 - 2.24;P < 0.001)。在90天至5年之间,与标准受体/低风险供体相比,只有标准受体/高风险供体死亡或移植物失败的概率增加(HR 1.140,CI 1.020 - 1.274;P = 0.021)。
LVAD受体,无论供体风险高低,与标准受体相比,早期(而非晚期)生存率更差,早期并发症更多。我们发现,不良供体特征对LVAD桥接受体结局的预测性低于标准受体。